Program
mosunetuzumab
Also written as “Mosunetuzumab”, “Mosunetuzumab (IV)” and “Mosunetuzumab (SC)”.
Its studies are mostly in Lymphoma, Follicular · Lymphoma, B-Cell · Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lupus Nephritis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 137 open or running | phase 3since Jan 13, 2021 | Jul 14, 2015 | Jul 31, 2027phase 2 · NCT05207670 |
| Ipsen | 10 open or running | phase 2since Dec 29, 2021 | Dec 29, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2015First study: phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellNew to Hoffmann-La RocheHoffmann-La Roche · NCT02500407 · 713 enrolled · United States, Australia, Canada and more
- Sep 10, 20183 phase 2 studiesHoffmann-La Roche · NCT03671018, NCT03677154, NCT03677141
- Jan 27, 2020Phase 2 study in Lymphoma, FollicularHoffmann-La Roche · NCT04246086 · 237 enrolled · United States, China, France and more
- Mar 17, 2020Phase 1 study in Lymphoma, B-CellHoffmann-La Roche · NCT04313608 · 23 enrolled · Australia
- Jan 13, 2021Phase 3 study in RecurrenceHoffmann-La Roche · NCT04712097 · 478 enrolled · United States, Australia, Brazil and more
- Oct 12, 2021Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT05091424 · 332 planned · United States, Australia, China and more
- Dec 6, 2021Phase 3 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT05171647 · 208 enrolled · United States, Argentina, Brazil and more
- Dec 10, 2021Phase 1 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT05155345 · 15 enrolled · United States, Moldova, Republic of, Poland
- Dec 15, 2021Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT05207670 · 320 enrolled · United States
- Dec 29, 2021Ipsen's first study: phase 2 study in Hematologic NeoplasmsNew to IpsenIpsen · NCT05205252 · United States
- Mar 31, 2022Phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT05315713 · 8 enrolled · United States, Australia, Belgium and more
- Feb 2, 2026Phase 2 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT07598396 · 30 planned · Argentina, Brazil, Colombia and more
- Nov 16, 2026Primary completion moved from 2028-02-28 to 2028-08-11Date moved laterphase 2 · +5 months · NCT07598396
Ahead
- Jul 31, 2027Primary completion: phase 2 study in Lymphoma, Non-HodgkinHoffmann-La Roche · NCT05207670
- Aug 11, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicHoffmann-La Roche · NCT07598396
- Sep 6, 2030Primary completion: phase 2 study in Lymphoma, FollicularHoffmann-La Roche · NCT04246086
- Feb 10, 2031Primary completion: phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellHoffmann-La Roche · NCT05091424
TargetBeta
“T cell surface glycoprotein CD3 binding agent; B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule | Johnson & Johnson | phase 1 | 3 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07598396Lupus Erythematosus, Systemic · Argentina, Brazil, Colombia and more | 2 | Recruiting | Hoffmann-La Roche | Aug 11, 2028 | 30 |
| NCT05315713Lymphoma, Non-Hodgkin · United States, Australia, Belgium and more | 2 | Terminated | Hoffmann-La Roche | Jul 19, 2023 | 8 |
| NCT05205252Hematologic Neoplasms · United States | 2 | Withdrawn | Ipsen | Jul 5, 2023 | 0 |
| NCT05207670Lymphoma, Non-Hodgkin · United States | 2 | Active, not recruiting | Hoffmann-La Roche | Jul 31, 2027 | 320 |
| NCT05155345Lupus Erythematosus, Systemic · United States, Moldova, Republic of, Poland | 1 | Completed | Hoffmann-La Roche | Dec 17, 2024 | 15 |
| NCT05171647Lymphoma, Non-Hodgkin · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Feb 17, 2025 | 208 |
| NCT05091424Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, China and more | 1 | Recruiting | Hoffmann-La Roche | Feb 10, 2031 | 332 |
| NCT04712097Recurrence · United States, Australia, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 3, 2026 | 478 |
| NCT04313608Lymphoma, B-Cell · Australia | 1 | Completed | Hoffmann-La Roche | Oct 26, 2021 | 23 |
| NCT04246086Lymphoma, Follicular · United States, China, France and more | 2 | Active, not recruiting | Hoffmann-La Roche | Sep 6, 2030 | 237 |
| NCT03677154Lymphoma, Large B-Cell, Diffuse · United States, Israel, Poland and more | 2 | Completed | Hoffmann-La Roche | Aug 7, 2025 | 188 |
| NCT03677141Lymphoma, B-Cell · United States, Austria, France and more | 2 | Completed | Hoffmann-La Roche | Oct 12, 2023 | 117 |
| NCT03671018Lymphoma, B-Cell · United States, Belgium, Canada and more | 2 | Active, not recruiting | Hoffmann-La Roche | Jan 30, 2024 | 422 |
| NCT02500407Leukemia, Lymphocytic, Chronic, B-Cell · United States, Australia, Canada and more | 2 | Completed | Hoffmann-La Roche | May 21, 2024 | 713 |
How it is read
Names in the registry
- “Mosunetuzumab”, 8 entries
- “Mosunetuzumab (IV)”, 2 entries
- “Mosunetuzumab (SC)”, 2 entries
- “Mosunetuzumab (Cohorts A-C)”, 1 entry
- “Mosunetuzumab (Cohorts D-E)”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Follicular, 3 studies
- Lymphoma, B-Cell, 3 studies
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.